ReviewToxins2018
Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease.
Review in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 90 citations in OpenAlex.
- Impact of Chronic Kidney Disease Severity on Clinical Outcomes After Drug-Eluting Stent Implantation: A Propensity Score-Matched Analysis.Clinical cardiology · 2026Article
- Serum metabolomics identifies gut-derived uremic toxins and bile acid dysregulation associated with chronic kidney disease severity.Scientific reports · 2026Article
- Serotonin, Kynurenine, and Indole Pathways of Tryptophan Metabolism in Humans in Health and Disease.Nutrients · 2026Review
- Metabolic biomarkers for predicting onset and severity of CAR-T therapy-induced cytokine release syndrome in multiple myeloma.Frontiers of medicine · 2025Article
- Novel Role of Tryptophan Metabolic Pathway in Mediating Peroxisomal Dysfunction in High-Dose Voclosporin-Induced Acute Kidney Injury.Journal of the American Society of Nephrology : JASN · 2025Article
- Impact of Maternal High-Fat Diet on Offspring Cardiovascular-Kidney-Metabolic Health: Spotlight on Oxidative Stress.Antioxidants (Basel, Switzerland) · 2025Review
- Observational
- Breastfeeding and Future Cardiovascular, Kidney, and Metabolic Health-A Narrative Review.Nutrients · 2025Review
- Unveiling the role of sex in the metabolism of indoxyl sulfate and apixaban.Scientific reports · 2025Article
- Animal Models for Studying Developmental Origins of Cardiovascular-Kidney-Metabolic Syndrome.Biomedicines · 2025Review
- Understanding Vascular Calcification in Chronic Kidney Disease: Pathogenesis and Therapeutic Implications.International journal of molecular sciences · 2024Review
- Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Review
- Sex differences in fetal kidney reprogramming: the case in the renin-angiotensin system.Pediatric nephrology (Berlin, Germany) · 2024Review
- Metabolic Assessment in Non-Dialysis Patients with Chronic Kidney Disease.Journal of inflammation research · 2024Article
- New insights into healthy ageing, inflammageing and frailty using metabolomics.Frontiers in aging · 2024Review
- Study of the association between serum levels of kynurenine and cardiovascular outcomes and overall mortality in chronic kidney disease.Clinical kidney journal · 2024Article
- The in-vitro influence of urea concentration on thromboelastrography in patients with and without end stage renal disease.American journal of surgery · 2023Article
- Ferroptosis of Endothelial Cells Triggered by Erythrophagocytosis Contributes to Thrombogenesis in Uremia.Thrombosis and haemostasis · 2023Article
- An Overview of Chronic Kidney Disease Pathophysiology: The Impact of Gut Dysbiosis and Oral Disease.Biomedicines · 2023Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic kidney disease (CKD) display an elevated risk of thrombosis. Thrombosis occurs in cardiovascular events, such as venous thromboembolism, stroke, and acute coronary syndrome, and is a cause of hemodialysis vascular access dysfunction. CKD leads to the accumulation of uremic toxins, which exerts toxic effects on blood and the vessel wall. Some uremic toxins result from tryptophan metabolization in the gut through the indolic and the kynurenine pathways. An increasing number of studies are highlighting the link between such uremic toxins and thrombosis in CKD. In this review, we describe the thrombotic mechanisms induced by tryptophan-derived uremic toxins (TDUT). These mechanisms include an increase in plasma levels of procoagulant factors, induction of platelet hyperactivity, induction of endothelial dysfunction/ impairment of endothelial healing, decrease in nitric oxide (NO) bioavailability, and production of procoagulant microparticles. We focus on one important prothrombotic mechanism: The induction of tissue factor (TF), the initiator of the extrinsic pathway of the blood coagulation. This induction occurs via a new pathway, dependent on the transcription factor Aryl hydrocarbon receptor (AhR), the receptor of TDUT in cells. A better understanding of the prothrombotic mechanisms of uremic toxins could help to find novel therapeutic targets to prevent thrombosis in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.